Chase Investment Counsel Corp Buys Shares of 20,000 Lantheus Holdings, Inc. $LNTH

Chase Investment Counsel Corp bought a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 20,000 shares of the medical equipment provider’s stock, valued at approximately $2,218,000.

Several other institutional investors and hedge funds also recently modified their holdings of the business. M&T Bank Corp acquired a new position in shares of Lantheus during the 4th quarter worth approximately $370,950,000. Farallon Capital Management LLC lifted its stake in Lantheus by 56.1% in the 4th quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock valued at $361,199,000 after buying an additional 1,950,252 shares in the last quarter. Reinhart Partners LLC. lifted its stake in Lantheus by 2.2% in the 2nd quarter. Reinhart Partners LLC. now owns 1,599,379 shares of the medical equipment provider’s stock valued at $177,437,000 after buying an additional 34,501 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Lantheus by 3.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,415,463 shares of the medical equipment provider’s stock valued at $94,202,000 after buying an additional 44,374 shares during the last quarter. Finally, Carmignac Gestion grew its holdings in Lantheus by 18.4% during the 1st quarter. Carmignac Gestion now owns 1,328,000 shares of the medical equipment provider’s stock valued at $100,729,000 after buying an additional 206,000 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Stock Performance

Shares of Lantheus stock opened at $100.95 on Monday. Lantheus Holdings, Inc. has a fifty-two week low of $49.67 and a fifty-two week high of $111.86. The firm has a market cap of $6.59 billion, a PE ratio of 24.38 and a beta of -0.03. The business’s fifty day moving average is $104.23 and its two-hundred day moving average is $89.34. The company has a quick ratio of 2.89, a current ratio of 3.06 and a debt-to-equity ratio of 0.43.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $1.30 by $0.25. The business had revenue of $388.18 million during the quarter, compared to the consensus estimate of $363.23 million. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.The business’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.57 earnings per share. Analysts anticipate that Lantheus Holdings, Inc. will post 4.5 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on LNTH shares. B. Riley Financial reissued a “buy” rating on shares of Lantheus in a report on Wednesday, July 29th. Brookline Capital Markets lowered Lantheus from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. CJS Securities cut Lantheus from a “market outperform” rating to a “market perform” rating in a research report on Tuesday, August 4th. Weiss Ratings downgraded shares of Lantheus from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday. Finally, Mizuho reduced their target price on shares of Lantheus from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Wednesday, July 29th. Five equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, Lantheus currently has a consensus rating of “Hold” and an average target price of $108.11.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.